Regeneron Pharmaceuticals (NASDAQ:REGN) Cut to Hold at StockNews.com

StockNews.com lowered shares of Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) from a buy rating to a hold rating in a report released on Friday morning.

Several other brokerages also recently weighed in on REGN. Oppenheimer cut their target price on shares of Regeneron Pharmaceuticals from $825.00 to $775.00 and set an outperform rating for the company in a research note on Tuesday, February 8th. BMO Capital Markets restated a buy rating and set a $780.00 target price on shares of Regeneron Pharmaceuticals in a research report on Friday, February 11th. Morgan Stanley boosted their price target on Regeneron Pharmaceuticals from $605.00 to $632.00 and gave the company an equal weight rating in a report on Tuesday, April 12th. Truist Financial decreased their price objective on Regeneron Pharmaceuticals from $754.00 to $728.00 and set a buy rating on the stock in a report on Tuesday, February 8th. Finally, Zacks Investment Research upgraded Regeneron Pharmaceuticals from a hold rating to a strong-buy rating and set a $694.00 target price for the company in a research note on Monday, January 10th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of Buy and a consensus target price of $724.63.

Shares of NASDAQ REGN opened at $599.77 on Friday. The firm’s 50-day moving average is $677.70 and its two-hundred day moving average is $644.67. The company has a market capitalization of $65.10 billion, a PE ratio of 8.50, a price-to-earnings-growth ratio of 1.12 and a beta of 0.25. Regeneron Pharmaceuticals has a 12-month low of $492.13 and a 12-month high of $747.42. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.76 and a quick ratio of 3.07.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) last posted its earnings results on Wednesday, May 4th. The biopharmaceutical company reported $11.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.78 by $1.71. The firm had revenue of $2.97 billion for the quarter, compared to analyst estimates of $2.69 billion. Regeneron Pharmaceuticals had a return on equity of 50.10% and a net margin of 48.06%. Regeneron Pharmaceuticals’s revenue was up 17.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $10.09 EPS. On average, analysts forecast that Regeneron Pharmaceuticals will post 43.03 EPS for the current fiscal year.

In related news, CFO Robert E. Landry sold 325 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, April 8th. The shares were sold at an average price of $737.79, for a total transaction of $239,781.75. Following the transaction, the chief financial officer now owns 28,744 shares in the company, valued at approximately $21,207,035.76. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Robert E. Landry sold 83 shares of the business’s stock in a transaction on Thursday, March 17th. The stock was sold at an average price of $686.00, for a total transaction of $56,938.00. The disclosure for this sale can be found here. Insiders have sold a total of 44,559 shares of company stock worth $30,297,368 in the last 90 days. Company insiders own 10.76% of the company’s stock.

A number of hedge funds have recently modified their holdings of REGN. Advisor Group Holdings Inc. lifted its holdings in Regeneron Pharmaceuticals by 8.0% in the 3rd quarter. Advisor Group Holdings Inc. now owns 11,582 shares of the biopharmaceutical company’s stock worth $6,995,000 after buying an additional 855 shares in the last quarter. Moors & Cabot Inc. raised its stake in shares of Regeneron Pharmaceuticals by 4,258.2% in the 3rd quarter. Moors & Cabot Inc. now owns 55,000 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 53,738 shares in the last quarter. Keybank National Association OH raised its stake in shares of Regeneron Pharmaceuticals by 39.6% in the 3rd quarter. Keybank National Association OH now owns 822 shares of the biopharmaceutical company’s stock valued at $497,000 after purchasing an additional 233 shares in the last quarter. Toronto Dominion Bank raised its stake in shares of Regeneron Pharmaceuticals by 24.2% in the 3rd quarter. Toronto Dominion Bank now owns 57,449 shares of the biopharmaceutical company’s stock valued at $34,766,000 after purchasing an additional 11,198 shares in the last quarter. Finally, Checchi Capital Advisers LLC raised its stake in shares of Regeneron Pharmaceuticals by 4.6% in the 3rd quarter. Checchi Capital Advisers LLC now owns 526 shares of the biopharmaceutical company’s stock valued at $318,000 after purchasing an additional 23 shares in the last quarter. Hedge funds and other institutional investors own 83.83% of the company’s stock.

Regeneron Pharmaceuticals Company Profile (Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

See Also

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.